Sunshine Biopharma, Inc.
SBFM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $35 | $24 | $4 | $0 |
| % Growth | 44.7% | 454.4% | 1,802.6% | – |
| Cost of Goods Sold | $24 | $16 | $3 | $0 |
| Gross Profit | $11 | $8 | $2 | $0 |
| % Margin | 30.6% | 34.6% | 39% | 48.4% |
| R&D Expenses | $1 | $2 | $1 | $1 |
| G&A Expenses | $14 | $10 | $9 | $2 |
| SG&A Expenses | $15 | $11 | $9 | $2 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $16 | $13 | $10 | $3 |
| Operating Income | -$6 | -$5 | -$27 | -$2 |
| % Margin | -16.7% | -19.9% | -621.3% | -1,068.2% |
| Other Income/Exp. Net | $0 | $1 | $0 | -$10 |
| Pre-Tax Income | -$5 | -$4 | -$27 | -$12 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$5 | -$5 | -$27 | -$12 |
| % Margin | -14.7% | -18.7% | -615.4% | -5,444.2% |
| EPS | -7.32 | -351.36 | -3,523.64 | -9,774.32 |
| % Growth | 97.9% | 90% | 64% | – |
| EPS Diluted | -7.32 | -351.36 | -3,523.64 | -9,520 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$4 | -$26 | -$12 |
| % Margin | -14.8% | -15.9% | -608.5% | -5,294.9% |